[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PE73099A1 - Utilizacion de las heparinas de bajo peso molecular para la prevencion y el tratamiento de los edemas cerebrales - Google Patents

Utilizacion de las heparinas de bajo peso molecular para la prevencion y el tratamiento de los edemas cerebrales

Info

Publication number
PE73099A1
PE73099A1 PE1998000385A PE00038598A PE73099A1 PE 73099 A1 PE73099 A1 PE 73099A1 PE 1998000385 A PE1998000385 A PE 1998000385A PE 00038598 A PE00038598 A PE 00038598A PE 73099 A1 PE73099 A1 PE 73099A1
Authority
PE
Peru
Prior art keywords
molecular weight
low molecular
heparines
prevention
treatment
Prior art date
Application number
PE1998000385A
Other languages
English (en)
Inventor
Veronique Mary
Jeremy Pratt
Jean-Marie Stutzmann
Andre Uzan
Florence Wahl
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of PE73099A1 publication Critical patent/PE73099A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

CARACTERIZADA PORQUE LA HEPARINA TIENE UN PESO MOLECULAR MEDIO COMPRENDIDO ENTRE 1000 Y 10000 DALTONS, EN PARTICULAR ENTRE 4000 Y 5000 DALTONS; PREFERENTEMENTE LAS HEPARINAS ESTAN CONSTITUIDAS POR OLIGOSACARIDOS QUE TIENEN UN ACIDO 2-O-SULFO-4-ENOPIRANOSURONICO EN UNA DE SUS EXTREMIDADES. TAMBIEN SE REFIERE A LA OBTENCION PARTICULARMENTE VENTAJOSA POR DESPOLIMERIZADO DE UN ESTER DE LA HEPARINA POR MEDIO DE UNA BASE TAL COMO SOSA. LAS HEPARINAS PUEDEN SER ENOXAPARINA, NADROPARINA, PARNAPARINA, REVIPARINA, ENTRE OTRAS; QUE PUEDEN SER UTILES PARA LA PREVENCION Y EL TRATAMIENTO DE LOS EDEMAS CEREBRALES
PE1998000385A 1997-05-28 1998-05-19 Utilizacion de las heparinas de bajo peso molecular para la prevencion y el tratamiento de los edemas cerebrales PE73099A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9706551A FR2763849B1 (fr) 1997-05-28 1997-05-28 Utilisation des heparines de bas poids moleculaire pour la prevention et le traitement des oedemes cerebraux

Publications (1)

Publication Number Publication Date
PE73099A1 true PE73099A1 (es) 1999-10-21

Family

ID=9507336

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000385A PE73099A1 (es) 1997-05-28 1998-05-19 Utilizacion de las heparinas de bajo peso molecular para la prevencion y el tratamiento de los edemas cerebrales

Country Status (24)

Country Link
US (1) US6579858B1 (es)
EP (1) EP0984787B1 (es)
JP (1) JP2002502387A (es)
KR (1) KR100562425B1 (es)
CN (1) CN1223351C (es)
AT (1) ATE225181T1 (es)
AU (1) AU742995B2 (es)
BR (1) BR9809180A (es)
CA (1) CA2290682A1 (es)
DE (1) DE69808455T2 (es)
DK (1) DK0984787T3 (es)
ES (1) ES2182321T3 (es)
FR (1) FR2763849B1 (es)
IL (2) IL132670A0 (es)
MA (1) MA24554A1 (es)
NO (1) NO317003B1 (es)
NZ (1) NZ501366A (es)
PE (1) PE73099A1 (es)
PT (1) PT984787E (es)
RU (1) RU2195287C2 (es)
TN (1) TNSN98072A1 (es)
TW (1) TW546141B (es)
WO (1) WO1998053834A1 (es)
ZA (1) ZA984433B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2787329B1 (fr) * 1998-12-17 2001-02-09 Aventis Pharma Sa Nouvelle application therapeutique des heparines de bas poids moleculaire
CA2458852A1 (en) * 2001-08-28 2003-03-06 Leo Pharma A/S Antithrombotic compositions comprising low molecular weight heparin and low molecular weight dermatan sulphate
ITMI20031023A1 (it) * 2003-05-21 2004-11-22 Umberto Cornelli Glicosaminoglicani aventi peso molecolare medio 2400 d atti al trattamento delle disfunzioni emozionali.
US11840565B2 (en) 2016-12-29 2023-12-12 University Of Miami Methods and compositions for treating virus-associated inflammation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2013092C1 (ru) * 1989-02-27 1994-05-30 Дагестанский государственный медицинский институт Способ лечения отека мозга при туберкулезном менингоэнцефалите

Also Published As

Publication number Publication date
US6579858B1 (en) 2003-06-17
NZ501366A (en) 2000-11-24
EP0984787A1 (fr) 2000-03-15
DE69808455D1 (de) 2002-11-07
DK0984787T3 (da) 2003-02-03
FR2763849A1 (fr) 1998-12-04
IL132670A0 (en) 2001-03-19
CA2290682A1 (fr) 1998-12-03
KR20010013073A (ko) 2001-02-26
CN1223351C (zh) 2005-10-19
ES2182321T3 (es) 2003-03-01
CN1257429A (zh) 2000-06-21
WO1998053834A1 (fr) 1998-12-03
FR2763849B1 (fr) 2000-09-15
IL132670A (en) 2010-05-31
ATE225181T1 (de) 2002-10-15
DE69808455T2 (de) 2003-07-03
EP0984787B1 (fr) 2002-10-02
JP2002502387A (ja) 2002-01-22
NO995539D0 (no) 1999-11-12
NO995539L (no) 1999-11-12
KR100562425B1 (ko) 2006-03-17
PT984787E (pt) 2003-01-31
AU742995B2 (en) 2002-01-17
RU2195287C2 (ru) 2002-12-27
BR9809180A (pt) 2000-08-01
TNSN98072A1 (fr) 2005-03-15
ZA984433B (en) 1998-12-28
TW546141B (en) 2003-08-11
NO317003B1 (no) 2004-07-19
MA24554A1 (fr) 1998-12-31
AU7776098A (en) 1998-12-30

Similar Documents

Publication Publication Date Title
ES2165990T3 (es) Thip para el tratamiento de trastornos del sueño.
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
UA27911C2 (uk) Засіб для лікування або запобігання фізіологічних розладів, які викликані надлишком тахікініну
PT979096E (pt) Tratamento de enfartes atraves da inibicao de nf-kb
DK0873097T3 (da) Bandagesystem
DE69834658D1 (de) Verwendung von aminothiolverbindungen zur behandlung von nerven- und nieren-erkrankungen und der arzneimitteltoxizität
ES2082887T3 (es) Flupirtina en combinacion con antiparkinsonianos para combatir espasmos musculares.
KR880012218A (ko) 캘폰 유도체를 사용한 다발성 경화증의 치료방법
ES2083597T3 (es) Preparacion farmaceutica para el tratamiento del tiempo de coagulacion prolongado.
ES2123499T3 (es) Metodos y composiciones para tratamiento de infecciones virales.
PE73099A1 (es) Utilizacion de las heparinas de bajo peso molecular para la prevencion y el tratamiento de los edemas cerebrales
SE9601395D0 (sv) New therapeutic treatment 1
ES2181702T3 (es) Derivados de melatonina para su uso en el tratamiento de enfermedad es del sueño.
SE9601396D0 (sv) New therapeutic treatment 2
PT817635E (pt) Utilizacao de compostos de tiazepina e oxazepina para a inibicao do vih, herpesvirus e supressores do sitema imunitario
ECSP003590A (es) Compuestos calcioliticos
ES1022449Y (es) Aparato terapeutica para tratamiento de sintomas ocasionados por enfermedades.
DK671087D0 (da) Anvendelse af 5-aryl-3h-1,2,4-triazol-3-oner som antikonvulsiva
MX9203362A (es) Composicion diuretica de benazepril/tiazida de dosis baja, para el tratamiento de la hipertension
AR015537A1 (es) Uso de brinzolamida para la manufactura de un medicamento para tratar o prevenir edema de retina.
ES2190499T3 (es) Uso de antagonistas de bradiquinina para la preparacion de medicamentos para el tratamiento y la prevencion de la enfermedad de alzheimer.
DE69635282D1 (de) Behandlung der exzessiven aggressivität mit olanzapine
ES2167942T3 (es) Empleo de 2-aminotetralinas 6,7-sustituidas apropiadas para la preparacion de una composicion farmaceutica para el tratamiento terapeutico de patologias inflamatorias y/o autoinmunes.
NO882724D0 (no) Smertepreparat.
ES2054097T3 (es) Agente para el tratamiento de enfermedades inflamatorias cronicas del intestino.

Legal Events

Date Code Title Description
FC Refusal